INDIVIDUAL ARTICLE: NECOM 7: Real-World Cases on Preventive and Treatment Using Skin Care for Cancer Treatment-Related Skin Reactions

As cancer prevalence continues to increase in Nordic countries, the amount of dermatological adverse events, termed cutaneous adverse events (cAEs), will also increase. The Nordic European Cutaneous Oncodermatology Management (NECOM) group aims to provide evidence-based guidance on how to treat and manage cAEs with an emphasis on supportive skincare regimens to improve patients' quality of life. The presented real-world cases demonstrate the use of the previous 6 NECOM recommendations in clinical practice. Experts in supportive oncodermatology share real patient cases and cAE treatment plans to serve as a guide for future healthcare providers. The cases highlight the use of daily skincare regimens containing gentle cleansers, moisturizers, and sunscreen that help to protect the skin from severe skin toxicities and help repair the skin barrier. Patients who were prescribed a daily skincare regimen consisting of Lipikar Syndet AP+ cleanser, Lipikar Baume AP+M, Cicaplast baume B5+, and Anthelios UVMUNE SPF50+ sunscreen (La Roche-Posay) found that their cAEs were less severe and symptomatic. The products in the recommended skincare regimen have all been tested for tolerance on patients undergoing cancer treatment. NECOM advisors emphasize the importance of selecting the right skincare products that will best nourish and heal sensitive skin and encourage patients and clinicians to encourage a proactive approach to skincare before, during, and after cancer-targeted therapies.  .